title: Biocompatible peritoneal dialysis solution preserves residual renal function.
abstract: OBJECTIVE
  The long-term effects of biocompatible peritoneal dialysis (PD) solution on residual renal function (RRF), inflammation, adipokines and metabolic acidosis are controversial. We evaluated the effects of biocompatible PD solution in continuous ambulatory PD (CAPD) patients for an additional 12-month period.
  
  
  METHODS
  Among 91 incident patients who started CAPD with either biocompatible PD solution (Balance®, Fresenius; LS, n = 48) or conventional PD solution (CAPD/DPCA®, Fresenius; CS, n = 43), 63 patients, who were followed for 12 months, were enrolled and followed for an additional 12 months.
  
  
  RESULTS
  After 24 months of treatment, the glomerular filtration rate (GFR) of the LS group was twofold higher compared to the CS group (33.5 ± 30.7 vs. 16.3 ± 17.9 l/week/1.73 m(2), respectively, p = 0.021). In a subgroup of patients with an initial GFR >2 ml/min/1.73 m(2), the GFR of the LS group was significantly higher than the rate of the CS group after 24 months (43.7 ± 30.5 vs. 18.6 ± 19.0 l/week/1.73 m(2), respectively, p = 0.042). Over a 24-month period, effluent cancer antigen-125 levels were significantly increased in the LS group compared to the CS group, while effluent interleukin-6 levels did not differ between the two groups. The serum tCO(2) levels were consistently higher in the LS group compared to the CS group.
  
  
  CONCLUSIONS
  We found that the effect of LS on preserving RRF may be maintained over a 24-month treatment period in CAPD patients, and LS use may have other benefits, such as the correction of metabolic acidosis.
authors.affiliation: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
authors.forename: Sejoong
authors.initials: S
authors.lastname: Kim
authors.forename: Kook-Hwan
authors.initials: KH
authors.lastname: Oh
authors.forename: Jieun
authors.initials: J
authors.lastname: Oh
authors.forename: Soo Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Wookyung
authors.initials: W
authors.lastname: Chung
authors.forename: Young Rim
authors.initials: YR
authors.lastname: Song
authors.forename: Ki Young
authors.initials: KY
authors.lastname: Na
authors.forename: Yun Kyu
authors.initials: YK
authors.lastname: Oh
authors.forename: Curie
authors.initials: C
authors.lastname: Ahn
authors.forename: Sung Gyun
authors.initials: SG
authors.lastname: Kim
authors.forename: Kathryn C B
authors.initials: KC
authors.lastname: Tan
mesh_terms: D000138:Acidosis / Q000378:metabolism / Q000628:therapy; D054392:Adipokines / Q000378:metabolism; D000328:Adult; D000368:Aged; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D015897:Comorbidity; D015314:Dialysis Solutions / Q000008:administration & dosage* / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate / Q000502:physiology; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000502:physiology*; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000379:methods*; D010537:Peritoneum / Q000502:physiology; D010538:Peritonitis / Q000401:mortality; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D054392:Adipokines; D001672:Biocompatible Materials; D015415:Biomarkers; D015314:Dialysis Solutions; D017127:Glycation End Products, Advanced